CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Nateglinide

那格列奈 杂质对照品Nateglinide Impurities

EP17 个杂质条目17 impurity entries

本页汇总 那格列奈 的 17 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 17 impurity reference standards of Nateglinide with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 那格列奈(Nateglinide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form
    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2011 · Thomas AB et al.  ·  PMID 23960763  ·  DOI
  2. 杂质研究Impurity studiesA validated stability indicating LC method for Nateglinide
    Drug development and industrial pharmacy · 2007 · Pathare DB et al.  ·  PMID 17520447  ·  DOI
  3. 分析方法Analytical MethodsDevelopment and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2008 · Varanasi KK et al.  ·  PMID 18342586  ·  DOI
  4. 分析方法Analytical MethodsAn Isocratic RP-HPLC Method for Simultaneous Quantification of Nateglinide and Furosemide: Application to In Vitro Caco-2 Intestinal Permeability Studies of Nanodrugs
    Biomedical chromatography : BMC · 2025 · Al-Sulaiti FK et al.  ·  PMID 41060075  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisAsymmetric α-amination of aldehydes at low catalytic loading: application to the synthesis of solriamfetol and nateglinide
    Organic & biomolecular chemistry · 2026 · Mehta R et al.  ·  PMID 42300936  ·  DOI

那格列奈 —— 原料药与杂质对照品Nateglinide — drug substance & impurities

共 18 个条目(含原料药本体)18 items incl. the drug substance
Nateglinide structure
EP原料药 APIAPI
那格列奈Nateglinide
Nateglinide
CAS No.105816-04-4
Chemical FormulaC19H27NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 5 (Nateglinide EP Impurity A) structure
EPA
那格列奈杂质5 (那格列奈EP杂质A)Nateglinide Impurity 5 (Nateglinide EP Impurity A)
Nateglinide Impurity 5 (Nateglinide EP Impurity A)
CAS No.7077-05-6
Chemical FormulaC10H18O2
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 2 (Nateglinide EP Impurity B) structure
EPB
那格列奈杂质2 (那格列奈EP杂质B)Nateglinide Impurity 2 (Nateglinide EP Impurity B)
Nateglinide Impurity 2 (Nateglinide EP Impurity B)
CAS No.105816-05-5
Chemical FormulaC19H27NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 6 (Nateglinide EP Impurity C) structure
EPC
那格列奈杂质6 (那格列奈EP杂质C)Nateglinide Impurity 6 (Nateglinide EP Impurity C)
Nateglinide Impurity 6 (Nateglinide EP Impurity C)
CAS No.105816-06-6
Chemical FormulaC19H27NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 1 (Nateglinide EP Impurity E) structure
EPE
那格列奈杂质1 (那格列奈EP杂质E)Nateglinide Impurity 1 (Nateglinide EP Impurity E)
Nateglinide Impurity 1 (Nateglinide EP Impurity E)
CAS No.105746-45-0
Chemical FormulaC18H25NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 7 (Nateglinide EP Impurity F) structure
EPF
那格列奈杂质7 (那格列奈EP杂质F)Nateglinide Impurity 7 (Nateglinide EP Impurity F)
Nateglinide Impurity 7 (Nateglinide EP Impurity F)
CAS No.944746-48-9
Chemical FormulaC28H36N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 3 (Nateglinide EP Impurity G) structure
EPG
那格列奈杂质3 (那格列奈EP杂质G)Nateglinide Impurity 3 (Nateglinide EP Impurity G)
Nateglinide Impurity 3 (Nateglinide EP Impurity G)
CAS No.187728-85-4
Chemical FormulaC21H31NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 1-d5 (Nateglinide EP Impurity E-d5) structure
EPE-D5
那格列奈杂质1-d5 (那格列奈EP杂质E-d5)Nateglinide Impurity 1-d5 (Nateglinide EP Impurity E-d5)
Nateglinide Impurity 1-d5 (Nateglinide EP Impurity E-d5)
CAS No.1356011-67-0
Chemical FormulaC18H20D5NO3
Purity>95%询价On request
Nateglinide Impurity 7-d5 (Nateglinide EP Impurity F-d5) structure
EPF-D5
那格列奈杂质7-d5 (那格列奈EP杂质F-d5)Nateglinide Impurity 7-d5 (Nateglinide EP Impurity F-d5)
Nateglinide Impurity 7-d5 (Nateglinide EP Impurity F-d5)
CAS No.1356354-42-1
Chemical FormulaC28H31D5N2O4
Purity>95%询价On request
Nateglinide Impurity 3-d5 (Nateglinide EP Impurity G-d5) structure
EPG-D5
那格列奈杂质3-d5 (那格列奈EP杂质G-d5)Nateglinide Impurity 3-d5 (Nateglinide EP Impurity G-d5)
Nateglinide Impurity 3-d5 (Nateglinide EP Impurity G-d5)
CAS No.1356929-50-4
Chemical FormulaC21H26D5NO3
Purity>95%询价On request
Nateglinide Impurity 4 structure
4
那格列奈杂质4Nateglinide Impurity 4
Nateglinide Impurity 4
CAS No.105746-47-2
Chemical FormulaC20H29NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 8 (Nateglinide Acyl-Beta-D-glucuronide) structure
8
那格列奈杂质8 (那格列奈酰基-Beta-D- 葡糖苷酸)Nateglinide Impurity 8 (Nateglinide Acyl-Beta-D-glucuronide)
Nateglinide Impurity 8 (Nateglinide Acyl-Beta-D-glucuronide)
CAS No.183996-85-2
Chemical FormulaC25H35NO9
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 10 structure
10
那格列奈杂质10Nateglinide Impurity 10
Nateglinide Impurity 10
CAS No.183997-00-4
Chemical FormulaC14H21NO4
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 11 structure
11
那格列奈杂质11Nateglinide Impurity 11
Nateglinide Impurity 11
CAS No.7084-93-7
Chemical FormulaC10H18O2
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 13 structure
13
那格列奈杂质13Nateglinide Impurity 13
Nateglinide Impurity 13
CAS No.1357003-01-0
Chemical FormulaC25H35NO9
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 15 structure
15
那格列奈杂质15Nateglinide Impurity 15
Nateglinide Impurity 15
CAS No.183996-82-9
Chemical FormulaC19H27NO4
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 16 structure
16
那格列奈杂质16Nateglinide Impurity 16
Nateglinide Impurity 16
CAS No.491828-09-2
Chemical FormulaC19H27NO3
Purity>95%询价On request
10mg25mg50mg100mg
Nateglinide Impurity 17 structure
17
那格列奈杂质17Nateglinide Impurity 17
Nateglinide Impurity 17
CAS No.958230-63-2
Chemical FormulaC20H29NO3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

那格列奈 —— 研究文献与合成路线Nateglinide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 那格列奈 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Nateglinide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A validated stability indicating LC method for Nateglinide
    Pathare DB, Jadhav AS, Shingare MS · Drug development and industrial pharmacy · 2007 · 被引 4cited 4
  2. Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form
    Thomas AB, Patil SD, Nanda RK, et al. · Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2011 · 被引 11cited 11

合成与制备工艺专利Synthesis & process patents

  1. A PROCESS FOR THE PREPARATION OF NATEGLINIDE
    KANKAN RAJENDRA NARAYANRAO, RAO DHARMARAJ RAMACHANDRA, BIRARI DILIP RAMDAS · 公开号 WO2011157986WO2011157986 · 2011
  2. NATEGLINIDE-CONTAINING PREPARATION
    — · 公开号 JP2012046534JP2012046534 · 2012
  3. PROCESS FOR THE PREPARATION OF CHIRALLY PURE NATEGLINIDE
    GAZDAG MARIA, GIZUR TIBOR, HEGEDUS BELA, SZEMZO ATTILA, et al. · 公开号 US2010256414US2010256414 · 2010
  4. NATEGLINIDE-CONTAINING PREPARATION
    NINOMIYA NOBUTAKA, MAKINO CHISATO, YABUKI AKIRA · 公开号 US2009203791US2009203791 · 2009
  5. PROCESS FOR SYNTHESIZING HIGHLY PURE NATEGLINIDE POLYMORPHS
    SRINIVASAN CHIDAMBARAM VENKATESWARAN, SARIN GURDEEP SINGH, WADHWA LALIT · 公开号 WO2008096373WO2008096373 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

那格列奈 杂质谱研究要点Nateglinide — impurity profiling notes

下面这些是拿到 那格列奈 的 18 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 18 impurity entries for Nateglinide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances